Article
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.
Clinical and translational science - 1 Dec 2025
Norton Nadine, Larson Nicholas B, Jenkins Gregory D, Beumer Jan H, Langevin Brooke, Gobbaru Jogarao, Morris Michael J, Nakamura Yusuke, Kroetz Deanna L, Zhu Hao-Jie, O'Donnell Peter H, Lewis Lionel D, Hertz Daniel L
Abstract excerpt
Enzalutamide and abiraterone are hormonal treatments that improve survival in metastatic castration-resistant prostate cancer. Identifying genetic variants associated with the clearance of these drugs may aid in improved dosing and outcomes. We performed genetic association studies of enzalutamide and abiraterone oral clearance in the Alliance A031201 clinical trial. Genome-wide genotyping was performed with the...
Topics
Join the communities discussing this publication.